This newsletter presents you the following key sessions:
1. PODCAST: Maha Hussain about the IMvigor010 study
2. Adjuvant osimertinib induces significant reduction in the risk of disease recurrence or death in patients with
stage IB-IIIA EGFR mutation-positive non-small cell lung cancer
3. Intracranial efficacy of tucatinib in metastatic HER2-positive breast cancer
4. Confirmed long-term benefit of adjuvant dabrafenib-trametinib in patients with resected stage III BRAF
V600-mutant melanoma
5. Addition of darolutamide to androgen deprivation therapy significantly prolongs overall survival in men
with non-metastatic castration-resistant prostate cancer
Please consult the prescribing information before prescribing via https://www.famhp.be/en